Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

Roche Basel Switzerland

Roche pays $1bn-plus for stake in genomics specialist

Shares in Foundation Medicine Inc doubled following the announcement

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links